


(a)



[LP(a)] (a)
 po(a) LDL
 apob- 100
 APO(a)

LP(a) .[]
LP(a)
. []
apo(a)

The diagram illustrates a complex system of parallel operations. It features several horizontal rows of nodes, each representing a different path or component of the system. The nodes are interconnected by various operators such as plus (+), minus (-), multiplication (×), division (/), and square brackets []. The connections are organized into distinct vertical columns, suggesting a hierarchical or modular structure. A color scheme is used to distinguish different parts: red highlights certain nodes and connections, while blue highlights others, possibly indicating different types of data or flow paths. The overall structure is highly symmetrical and suggests a well-defined computational or logical process.

	(HDL-C) , (LDL-C)	(APOB ,APOAI)	APO
HDL-C	LDL-C		LP(a)

³ Randox

¹ Low Density Lipoprotein
² High Density Lipoprotein

(LDL-C+HDL-)
VLDL-C []
VLDL-C = C)
APOB ,APOAI ,LP(a)

BUN

Cabas Mira

Pesce-Stande

.1

	Mean± SD	Mean±SD	
> /	/ ± /	/ ± /	()
> /	± /	/ ± /	(Kg/m ²) BMI ¹
< /	/ ± /	/ ± /	/
< /	± /	±	(g/l)
> /	/ ± /	/ ± /	(mg/dl)
> /	± /	± /	(mg/dl) BUN
< /	±	±	(mg/dl)
< /	±	±	(mg/dl)
> /	±	±	(mg/dl) HDL-C
< /	±	±	(mg/dl) LDL-C
< /	±	±	(mg/dl) APOAI
< /	±	±	(mg/dl) APOB
< /	± /	± /	(mg/dl) LP(a)

1. Body Mass Index

	p	r	p	r	
	< /	+ /	< /	/	
	< /	+ /	< /	/	
	< /	+ /	< /	/	LDL-C
	< /	/	< /	/	HDL-C
/	< /	+ /	< /	/	APOAI
	< /	/	< /	/	APOB
	< /	+ /	< /	/	LP(a)

()

LP(a) ()
[] APOB

APOAI APOB , LDL-C,

.(p< /)
HDL-C)

LDL-, LP(a), APOB

```

graph TD
    C[C] --> APOB[APOB]
    C --> LDL[LDL]
    APOB --> LPa1[LP(a)]
    APOB --> APoB[APOb]
    LDL --> LPa2[LP(a)]
    LDL --> ESRD1[ESRD]
    LDL --> APOa[APoA]
    LPa2 --> APOa1[APO(a)]
    LPa2 --> LPa3[LP(a)]
    APOa1 --> LPa4[LP(a)]
    APOa1 --> ESRD2[ESRD]
    LPa3 --> LPa5[LP(a)]
    LPa3 --> LPa6[LP(a)]
    LPa5 --> Box1["[ ]"]
    Box1 --> APoB[APOB]
    LPa6 --> Box2["[ ]"]
    Box2 --> APoB
  
```

APOAI , LDL-C , LP(a) . APOB APOB

LP(a) APOB .[] LP(a)
B [] LP(a)

APOB APOAI , LDL-C ,

HDL-C LP(a) .[] LP(a)

²Noto

3 Doucel

⁴ Apolipoprotein(a)

¹ End Stage Renal Disease

- patients with glomerular proteinuria. *Nephrol Dial Transplant*. 1994; 9(3): 244-50.
- 7- Faucher C, Doucet C, Banmelon A, Chapman J, Jacobs C, Thillet J. Elevated lipoprotein (a) levels in primary nephrotic syndrome. *Am J Kidney Dis*. 1993 Dec; 22(6): 808-13 .
- 8- Stenvinkel P, Berglund L, Ericsson S, Alvestrand A, Angelin B, Eriksson M. Low density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome. *Eur J Clin Invest*. 1997 Feb; 27(2): 169-77 .
- 9- Thiery J, Ivandic B, Bahlmann G, Walli AK, Seidol D. Hyperlipoproteinemia in nephrotic syndrome. *Eur J Clin Invest*. 1996 Apr; 26(4): 316 -21.
- 10- Stein EA, Myers GL. Lipids, lipoproteins and apolipoproteins . In: Burtin A, editor, Tietz Textbook clinical chemistry, 2nd ed. Philadelphia: W.B Saunders, 1994 : 1002-93.
- 11- Pesce MA, Strande CS. A new micromethod for the determination of protein in cerebrospinal fluid and urine . *Clin Chem*. 1973 Nov; 19(11): 1265-7.
- 12- Henry JB. Clinical diagnosis and management by laboratory methods , 19th ed. Philadelphia: W.B Saunders ,1996: 140-71.
- 13- Oida K, Takai H, Maeda H, Takahashi S, Shimada A, Suzuki J, et al. Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. *Clin Chem*. 1992 Nov; 38(11): 2244-8.
- 14- Azrolan N, Brown CD, Thomas L, Hayek T, Zhao ZH, Roberts KG, et al. Cyclosporin A has divergent effects on plasma LDL, Cholesterol (LDL-C) and LP(a) levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of LP(a) concentrations in hemodialysis patients. *Arterioscler*. 1994 Sep; 14(9): 1393-8.
- 15- Vega G, Toto RD, Grundy SM. Metabolism of low density lipoproteins in nephrotic dyslipidemia: Comparison of hypercholesterolemia alone and combined hyperlipidemia. *Kidney Int*. 1995 Feb; 47(2): 579-86.
- 16- Stenvinkel P, Berglund L, Ericsson S, Alvestrand A, Angelin B, Eriksson M. Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the []
- LP(a)
- APOB
- APOB
- 1- Jialal I. Evolving lipoprotein risk factors: lipoprotein (a) and oxidized low-density lipoprotein . *Clin Chem*. 1998 Aug; 44(8PT2): 1827-32 .
- 2- Brown MS, Goldstein JL. Teaching old dogmas new tricks. *Nature*. 1987Nov; 330(6144): 113-4.
- 3- Scanu AM, Fless GM. Lipoprotein(a). Heterogeneity and biological relevance. *J Clin Invest*. 1990 Jun; 85(6): 1709-15.
- 4- Hong SY, Yang DH. Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrom. *Nephron* . 1995; 69(2): 125- 30.
- 5- Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. *Kidney Int*. 1993 Sep; 44(3): 638-42.
- 6- Gansevoort RT, Heeg JE, Dikkeschei FD, de zeeuw D, De Jong PE, Dullaart RPF. Symptomatic antiproteinuric treatment decreases serum lipoprotein(a) concentration in

nephrotic syndrom. Eur J Clin Invest. 1997 Feb; 27(2): 159-77.

17- Kawasaki Y, Suzuk J, Nozawa R, Suzuki S, Suzuki H. Prediction of relapse by plasma lipoprotein(a) concentration in children with steroid sensitive nephrotic syndrom . Nephrol. 2002; 92(4): 807-11.

18- Thabet MA, Salcedo JR, Chan JC. Hyperlipidemia in childhood nephrotic syndrom. Pediatr Nephrol. 1993 Oct; 77(5): 559-66.

19- Noto D, Barbagallo CM, Cascio AL, Cefaln AB, Cavera G, Caldarell R, et al. Lipoprotein(a) levels in relation to albumin concentration in children nephrotic syndrome. Kidney Int. 1999; 55(6): 2433 -9.

20- Doucet C, Mooser V, Gonbert S, Raymond F, Chapman J, Jacobs C, et al. Lipoprotein(a) in the nephrotic syndrom: Molecular analysis of lipoprotein(a) and apolipoprotein(a) fragments in plasma and urine . J AM Soc Nephrol. 2000; 11(3): 507-13.

21- Nanner C, Rader D, Bartens W, Kramet J, Brewer HB, Schollmeyer P, et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med. 1993 Aug; 119(4): 263-9.

22- Mangeais C, Braschi S, Ouguerram P, Maugeais P, Mahot p, Jacotot B. Lipoprotein kinetics in patients with analbuminemia: Evidence for the role of serum albumin in controlling lipoprotein metabolism. Arterioscler Thromb Vascbiol. 1997 Jul; 17(77): 1369-75.

23- Stenvinkel P, Berglund L, Heimburger D, Patterson E, Alvestrand A. Lipoprotein(a) in nephrotic syndrome. Kindney Int. 1993 Nov; 44(5): 1116-23.